BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 29387987)

  • 1. Detailed pathologic analysis on the co-occurrence of non-seminomatous germ cell tumor subtypes in matched orchiectomy and retroperitoneal lymph node dissections.
    Spratt DE; Suresh K; Osawa T; Schipper M; Jackson WC; Abugharib A; Lebastchi A; Smith D; Montgomery JS; Palapattu GS; Priya Kunju L; Wu A; Lew M; Tomlins SA; Chinnaiyan AM; Weizer AZ; Hafez KS; Kaffenberger SD; Udager A; Mehra R
    Med Oncol; 2018 Jan; 35(3):21. PubMed ID: 29387987
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Post-chemotherapy retroperitoneal teratoma in nonseminomatous germ cell tumors: Do predictive factors exist? Results from a national multicenter study.
    Dusaud M; Malavaud B; Bayoud Y; Sebe P; Hoepffner JL; Salomon L; Houlgatte A; Pignot G; Rigaud J; Fléchon A; Pfister C; Rouprêt M; Soulié M; Méjean A; Durand X
    J Surg Oncol; 2016 Dec; 114(8):992-996. PubMed ID: 27859263
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence of metastatic nonseminomatous germ cell tumor outside the boundaries of a modified postchemotherapy retroperitoneal lymph node dissection.
    Carver BS; Shayegan B; Eggener S; Stasi J; Motzer RJ; Bosl GJ; Sheinfeld J
    J Clin Oncol; 2007 Oct; 25(28):4365-9. PubMed ID: 17906201
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pathologic findings and clinical outcome of patients undergoing retroperitoneal lymph node dissection after multiple chemotherapy regimens for metastatic testicular germ cell tumors.
    Eggener SE; Carver BS; Loeb S; Kondagunta GV; Bosl GJ; Sheinfeld J
    Cancer; 2007 Feb; 109(3):528-35. PubMed ID: 17177200
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative Effectiveness of Risk-adapted Surveillance vs Retroperitoneal Lymph Node Dissection in Clinical Stage I Nonseminomatous Germ Cell Testicular Cancer: A Retrospective Follow-up Study of 81 Patients.
    Fan G; Zhang L; Yi L; Jiang ZQ; Ke Y; Wang XS; Xiong YY; Han WQ; Zhou X; Liu C; Yu X
    Asian Pac J Cancer Prev; 2015; 16(8):3267-72. PubMed ID: 25921130
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term oncological outcome after post-chemotherapy retroperitoneal lymph node dissection in men with metastatic nonseminomatous germ cell tumour.
    Fléchon A; Tavernier E; Boyle H; Meeus P; Rivoire M; Droz JP
    BJU Int; 2010 Sep; 106(6):779-85. PubMed ID: 20089110
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Robot-assisted retroperitoneal lymph node dissection (RA-RPLND) in the adolescent population.
    Glaser AP; Bowen DK; Lindgren BW; Meeks JJ
    J Pediatr Urol; 2017 Apr; 13(2):223-224. PubMed ID: 28262537
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Primary vs. post-chemotherapy retroperitoneal lymph node dissection (RPLND) in patients with presence of teratoma at orchiectomy.
    Williams SB; Kacker R; Steele GS; Richie JP
    Urol Oncol; 2012; 30(1):60-3. PubMed ID: 20189842
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Primary robotic retroperitoneal lymph node dissection following orchiectomy for testicular germ cell tumors: a single-surgeon experience.
    Supron AD; Cheaib JG; Biles MJ; Schwen Z; Allaf M; Pierorazio PM
    J Robot Surg; 2021 Apr; 15(2):309-313. PubMed ID: 32572754
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical outcome of postchemotherapy retroperitoneal lymph node dissection and predicting retroperitoneal histology in advanced nonseminomatous germ cell tumours of the testis].
    Li XD; Guo SJ; Chen SL; Liu ZF; Dong P; Zhang ZL; Jiang LJ; Yao K; Li YH; Han H; Qin ZK; Liu ZW; Zhou FJ
    Zhonghua Wai Ke Za Zhi; 2017 Aug; 55(8):603-607. PubMed ID: 28789511
    [No Abstract]   [Full Text] [Related]  

  • 11. Prognostic Value of Teratoma in Primary Tumor and Postchemotherapy Retroperitoneal Lymph Node Dissection Specimens in Patients With Metastatic Germ Cell Tumor.
    Taza F; Chovanec M; Snavely A; Hanna NH; Cary C; Masterson TA; Foster RS; Einhorn LH; Albany C; Adra N
    J Clin Oncol; 2020 Apr; 38(12):1338-1345. PubMed ID: 32134699
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical outcome following post-chemotherapy retroperitoneal lymph node dissection in men with intermediate- and poor-risk nonseminomatous germ cell tumour.
    Shayegan B; Carver BS; Stasi J; Motzer RJ; Bosl GJ; Sheinfeld J
    BJU Int; 2007 May; 99(5):993-7. PubMed ID: 17437432
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Retroperitoneal lymph node dissection for nonseminomatous germ cell testicular cancer: impact of patient selection factors on outcome.
    Stephenson AJ; Bosl GJ; Motzer RJ; Kattan MW; Stasi J; Bajorin DF; Sheinfeld J
    J Clin Oncol; 2005 Apr; 23(12):2781-8. PubMed ID: 15837993
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Outcome of Retroperitoneal Lymph Node Dissection after Chemotherapy in Patients with Pure Embryonal Carcinoma in the Orchiectomy Specimen.
    Dowling CM; Assel M; Musser JE; Meeks JJ; Sjoberg DD; Bosl G; Motzer R; Bajorin D; Feldman D; Carver BS; Sheinfeld J
    Urology; 2018 Apr; 114():133-138. PubMed ID: 29410311
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Laparoscopic and open retroperitoneal lymph-node dissection for clinical stage I nonseminomatous germ-cell testis tumors.
    Abdel-Aziz KF; Anderson JK; Svatek R; Margulis V; Sagalowsky AI; Cadeddu JA
    J Endourol; 2006 Sep; 20(9):627-31. PubMed ID: 16999613
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blood testis barrier revisited-Analysis of post-chemotherapy germ cell tumor orchidectomy and retroperitoneal lymph node dissection specimens.
    Gupta A; Noronha J; Bakshi G; Menon S; Pal M; Joshi A; Prabash K; Noronha V; Murthy V; Krishnattry R; Patil A; Prakash GJ
    J Surg Oncol; 2021 Mar; 123(4):1157-1163. PubMed ID: 33428791
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and Early Oncologic Effectiveness of Primary Robotic Retroperitoneal Lymph Node Dissection for Nonseminomatous Germ Cell Testicular Cancer.
    Pearce SM; Golan S; Gorin MA; Luckenbaugh AN; Williams SB; Ward JF; Montgomery JS; Hafez KS; Weizer AZ; Pierorazio PM; Allaf ME; Eggener SE
    Eur Urol; 2017 Mar; 71(3):476-482. PubMed ID: 27234998
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Post-chemotherapy retroperitoneal lymph node dissection in the management of metastatic testis cancer: the 16-year experience in an Irish setting.
    Considine S; Heaney R; Conroy R; Thornhill JA
    Ir J Med Sci; 2016 Nov; 185(4):901-907. PubMed ID: 26692387
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Robot - assisted laparoscopic retroperitoneal lymph node dissection in testicular tumor.
    Torricelli FC; Jardim D; Guglielmetti GB; Patel V; Coelho RF
    Int Braz J Urol; 2017; 43(1):171. PubMed ID: 28124545
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predicting necrosis in residual mass analysis after retroperitoneal lymph node dissection: a retrospective study.
    Miranda Ede P; Abe DK; Nesrallah AJ; dos Reis ST; Crippa A; Srougi M; Dall'Oglio MF
    World J Surg Oncol; 2012 Sep; 10():203. PubMed ID: 23021209
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.